PIPELINE
Pipeline details
[IL2102] SOS1 Inhibitor for RAS Driven Cancers
[IL2102] SOS1 Inhibitor for RAS Driven Cancers • Potentially best-in-class, orally available, small molecule SOS1 inhibitor for any RAS driven cancers which has shown strong activity against various KRAS mutants and wild types including KRAS G12C, G12D, G12V and KRAS G13C. • SOS1 is a pivotal switch that converts RAS from its inactive (off) state to its active (on) state, representing a novel therapeutic target in RAS-driven cancers Inhibition of the GTP exchange…
[IL2401] Cyclin K Degrader-Antibody-Conjugates for Solid Tumors
[IL2401] Cyclin K Degrader-Antibody-Conjugates for Solid Tumors• Developing the first Cyclin K Degrader as a novel DAC payload, administered via IV injection, intended for use as a first-line monotherapy or in combination with existing first-line therapies • The payload demonstrates enhanced potency and broader coverage across various solid tumor cells, with robust Cyclin K degradation observed in cancer cells• The platform allows for further pipeline expansion through combi…
[IL2112] ACKR3 PAM for Autoimmune and Fibrotic Diseases
[IL2112] ACKR3 PAM for Autoimmune and Fibrotic DiseasesØACKR3 PAM: Game Changing First-in-Class with a Unique MoA: •The ACKR3 PAM binds with the ACKR3 receptor and increases its affinity for the CXCL12 which enables ACKR3 to internalize and degrade CXCL12 intracellularly, leading to the reduction and normalization of the CXCL12 level, a key chemokine involved in immune cell recruitment and chronic inflammation, and its dysregulation is implicated in various autoimmune diseases, incl…